Free α-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 6, 2010, Pages 2841-2844

  Hirsch, Harry J ^a   Lahlou, Najiba ^b   Gillis, David ^c   Strich, David ^d   Rosenberg Hagen, Binyamina ^e   Chertin, Boris ^a   Farkas, Amicur ^a   Hartman, Hadassa ^f   Spitz, Irving M ^f  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b Centre Hospitalier Universitaire Cochin Saint Vincent de Paul ^*  (France)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d CLALIT HEALTH SERVICES   (Israel)

^e Misgav Ladach General Hospital Israel   (Israel)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADOTROPIN; HISTRELIN; LUTEINIZING HORMONE; DRUG DERIVATIVE; GONADORELIN;

ALPHA CHAIN; ARTICLE; CHILD; CLINICAL ARTICLE; DEVICE REMOVAL; DISEASE MARKER; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN SECRETING CELL; HUMAN; IMPLANT; LUTEINIZING HORMONE BLOOD LEVEL; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; RELIABILITY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; BLOOD; CONVALESCENCE; DELAYED RELEASE FORMULATION; DRUG IMPLANT; HYDROGEL; METABOLISM;

CHILD; DELAYED-ACTION PREPARATIONS; DRUG IMPLANTS; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLICLE STIMULATING HORMONE, HUMAN; GLYCOPROTEIN HORMONES, ALPHA SUBUNIT; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; HYDROGELS; LUTEINIZING HORMONE; PUBERTY, PRECOCIOUS; RECOVERY OF FUNCTION;

EID: 77954509163     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2078     Document Type: Article

References (14)

1. Roger M, Lahlou N, Chaussain JL 1996 Gonadotropin-releasing hormone testing in pediatrics. In: Ranke MB, ed. Diagnostics of endocrine function in children and adolescents. Heidelberg, Germany: Johann Ambriosius Barth Verlag; 346-369
2. Lerrant Y, Kottler ML, Bergametti F, Moumni M, Blumberg-Tick J, Counis R 1995 Expression of gonadotropin-releasing hormone (GnRH) receptor gene is altered by GnRH agonist desensitization in a manner similar to that of gonadotropin β-subunit genes in normal and castrated rat pituitary. Endocrinology 136:2803-2808
3. 6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty. J Clin Endocrinol Metab 65:946-953
4. Lahlou N, Carel JC, Chaussain JL, Roger M 2000 Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 13:723-737
5. Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, Lucas C, Chaussain JL 2002 Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 87:4111-4116
6. Hirsch HJ, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T, Gelber H, Spitz IM 2005 The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 116:e798-e802
7. Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, Saenger P, Shulman D, Silverman L, Flood L, Gray W, Tierney D 2007 Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 92:1697-1704
8. Rahhal S, Clarke WL, Kletter GB, Lee PA, Neely EK, Reiter EO, Saenger P, Shulman D, Silverman L, Eugster EA 26 February 2009 Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol DOI:10.1155/2009/812517
9. Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A 2000 An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol 163:838-844 (Pubitemid 30091628)
10. Kuzma P, Moo-Young A, Spitz I, Quandt H, Lindenberg T, Chertin B, Farkas A, Frick J, Schlegel P 1999 Hydron implant for continuous treatment of prostate cancer: twelve months and beyond. Proc 25th Annual Meeting of the Society for Biomaterials, Providence, RI, 1999
11. Schlegel PN, Kuzma P, Frick J, Farkas A, Gomahr A, Spitz I, Chertin B, Mack D, Jungwirth A, King P, Nash H, Bardin CW, Moo-Young A 2001 Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology 58:578-582
12. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, Wit JM 2009 Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 123:e752-e762
13. Clayton RN, Catt KJ 1981 Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function. Endocr Rev 2:186-209
14. Nafstad P, Samuelsen SO, Irgens LM, Bjerkedal T 2002 Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 110:e30